| Original language | English |
|---|---|
| Pages (from-to) | 843-851 |
| Journal | Breast Cancer Research and Treatment |
| Volume | 122 |
| Issue number | 3 |
| Publication status | Published - 2010 |
Cite this
}
Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years : A population-based analysis. / van Herk-Sukel, M.P.P.; van de Poll-Franse, L.V.; Voogd, A.C.; Nieuwenhuijzen, G.A.P.; Coebergh, J.W.W.; Herings, R.M.C.
In: Breast Cancer Research and Treatment, Vol. 122, No. 3, 2010, p. 843-851.Research output: Contribution to journal › Article › Scientific › peer-review
TY - JOUR
T1 - Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years
T2 - A population-based analysis
AU - van Herk-Sukel, M.P.P.
AU - van de Poll-Franse, L.V.
AU - Voogd, A.C.
AU - Nieuwenhuijzen, G.A.P.
AU - Coebergh, J.W.W.
AU - Herings, R.M.C.
PY - 2010
Y1 - 2010
M3 - Article
VL - 122
SP - 843
EP - 851
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
SN - 0167-6806
IS - 3
ER -